San Francisco, 29 November 2018, Global pointof care molecular diagnostics market is anticipated to reach USD 3.9
billion by 2024, according to a new report by Grand View Research, Inc. Ongoing
research & development to miniaturize molecular diagnostics testing that
provides enhanced near patient testing with high accuracy & lesser
turnaround times are major factors expected to reinforce the high growth
potential for POC MDx products.
Growing
demand for CLIA tests that are, by definition, portable and safe enough to be
used in non-laboratory settings such as pharmacy clinics, physician offices,
and home-care settings, is expected to drive demand in the market over the
forecast period. Ongoing research and development is continually supported and
funded by a number of major international entities including the national
governments of developed countries and high-value private funding agencies such
as the Bill & Melinda Gates Foundation.
Furthermore,
a growing portfolio of point-of-care testing capabilities that, had initially
been focused on screening, testing, and diagnosis of infectious diseases in
low-income developing countries, has been developing at a rapid pace over the
past decade to expand its potential market to a broader range of medical
faculties. Consequently, POC and molecular diagnosis tests are available and/or
are under development for cardiology monitoring, oncology testing, and
hematology testing.
Recent
advances in the development of microfluidics and genetic sequencing
instrumentation pave the way for development of cost-effective, highly accurate
and rapid testing platforms, which are able to be used as true POC systems.
This is a key factor that significantly contributes towards the favorably
funded, high growth potential environment prevalent in the point of care
molecular diagnostics market.
Access Full
Research Report On Point Of Care Molecular Diagnostics Market Analysis:
www.grandviewresearch.com/industry-analysis/point-of-care-poc-molecular-diagnostics-market
www.grandviewresearch.com/industry-analysis/point-of-care-poc-molecular-diagnostics-market
Further key findings from the report
suggest:
·
Application of POC MDx tests
for infectious diseases accounted for over 45% of market revenue in 2015. The
large share can be accounted for by the presence of an extensive portfolio of
the concerned tests with a number of major market entities. Furthermore,
growing disease burden of infectious diseases in developing as well as
developed countries is another factor the reinforces the dominance of this
segment.
·
PCR-based POC tests accounted
for the largest share of the market in 2015. Widespread usage of PCR-based
techniques for molecular diagnosis and commercialization of POC real time PCR
products such as the cobas LIAT by Roche have provided this segment with ample
opportunities for revenue generation and are expected to maintain a favorable
market environment over the forecast period.
·
North America was observed to
be the most lucrative region on this market and estimated to account for over
40% of the global revenue. presence of a technologically advanced medical
framework, sophisticated insurance & copayment system & high R&D
investment by governments and private funding organizations for the development
of POC MDx tests are major factors responsible for the region’s dominant market
position.
·
Key players operating in this
industry include Johnson & Johnson, Danaher Corp., Cepheid, Bio-Rad
Laboratories, bioMerieux, Becton Dickinson, Roche Diagnostics, Bayer
Healthcare, Alere Inc (Abbott), Abbott Laboratories among others.
Browse
More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has
segmented point of care molecular diagnostics market on the basis of workflow,
mode, services, and region:
Global Point
of Care Molecular Diagnostics Application Outlook (Revenue, USD Million, 2013 -
2024)
·
Infectious Diseases
·
Oncology
·
Hematology
·
Prenatal Testing
·
Endocrinology
·
Other Applications
Global Point
of Care Molecular Diagnostics Technology Outlook (Revenue, USD Million, 2013 -
2024)
·
PCR-based
·
Genetic Sequencing-based
·
Hybridization-based
·
Microarray-based
Global Point
of Care Molecular Diagnostics Test Location Outlook (Revenue, USD Million, 2013
- 2024)
·
OTC
·
POC
Global Point
of Care Molecular Diagnostics End-use Outlook (Revenue, USD Million, 2013 -
2024)
·
Decentralized Labs
·
Hospitals
·
Home-care
·
Assisted Living Healthcare
Facilities
·
Other uses
Point
of Care Molecular Diagnostics Regional Outlook (Revenue, USD Million, 2013 -
2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
China
o
Japan
·
Latin America
o
Brazil
·
MEA
o
South Africa
Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-point-of-care-poc-molecular-diagnostics-market
www.grandviewresearch.com/press-release/global-point-of-care-poc-molecular-diagnostics-market
About Grand View Research
Grand View
Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/
